TITLE

EXONHIT INITIATES PHASE II CLINICAL TRIAL FOR EHT 0201

PUB. DATE
December 2002
SOURCE
Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the launch by the company ExonHit Therapeutics of a clinical trial evaluating the effectiveness of EHT 0201 (pentoxyfylline) in patients suffering from amyotrophic lateral sclerosis.
ACCESSION #
8573854

 

Related Articles

  • Insulin-like growth factor significantly improves symptoms...  // Formulary;Jan1996, Vol. 31 Issue 1, p15 

    Reports that the recombinant human insulin-like growth factor appears to slow progression of amyotrophic lateral sclerosis (ALS) and improve functional ability according to the results of a survey. Side effects of drug; Dosage; Comment from Howard Natter, clinical assistant professor of...

  • Doe v. Wilson. Salyer, David R. // Issues in Law & Medicine;Winter90, Vol. 6 Issue 3, p319 

    Presents a United States court ruling related to euthanasia in patients suffering from amyotrophic lateral sclerosis. Case of patient Jane Doe who requested that her physician Dr. James P. Wilson disconnect her respirator; Consideration by Chancellor Allen High on previous legal precedents.

  • Support services important component of Rilutek launch. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the planned launch of Rhone-Poulenc Rhorer's (RPR) Rilutek riluzole drug for amyotrophic lateral sclerosis (ALS). Patient support services; Background information; Implications; Plans and expectations.

  • Diagnosing motor neurone disease. Chancellor, Andrew M. // BMJ: British Medical Journal (International Edition);3/16/96, Vol. 312 Issue 7032, p650 

    Discusses diagnostic strategies for motor neurone disease. Symptoms; Dilemma faced by the physician in diagnosing motor neurone disease; Conditions that resemble idiopathic motor neurone disease.

  • Motor neurone disease. Shneerson, John M. // BMJ: British Medical Journal (International Edition);8/3/96, Vol. 313 Issue 7052, p244 

    Focuses on motor neurone disease. Deterioration of bulbar function; Pathogenesis; Complications.

  • Understanding Lou Gehrig's disease.  // Patient Care;2/28/1997, Vol. 31 Issue 4, p16 

    Reports on the nationwide program to develop guidelines for the treatment of amyotyhrophic lateral sclerosis (ALS) in the United States. Prevalence of ALS in the country; Contact information for physicians and patients interested to participate in the program.

  • Lead content of neuromuscular tissue in amyotrophic lateral sclerosis Hoogstraten, J.; Hillier, C. R.; Petkau, A.; Sawatzky, A. // British Journal of Industrial Medicine;Oct1974, Vol. 31 Issue 4, p275 

    No abstract available.

  • Miraculous Mike. MacLean, Joshua // Stone Soup;Mar/Apr2001, Vol. 29 Issue 4, p23 

    Presents an article about a father who died of Lou Gehrig's disease.

  • ALS.  // Mayo Clinic Health Letter;Apr1996, Vol. 14 Issue 4, p4 

    Reports that despite progress there is still no cure for Lou Gehrigs disease (amyotrophic lateral sclerosis). Percentages on those who inherit it; Effects of the disease; Emerging clues about origins; Hope of developing new therapies; Drug approved for treatment. INSET: Lou Gehrig and Stephen...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics